{"filing":{"accession_number":"0001855644-26-000007","cik":"0001855644","ticker":"ZURA","company_name":"Zura Bio Ltd","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"zura-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1855644/000185564426000007/zura-20260811.htm"},"events":[{"id":26878,"run_id":24446,"accession_number":"0001855644-26-000007","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Zura Bio issued a press release on August 11, 2026 announcing its second quarter 2026 financial results, including consolidated balance sheets, statements of operations, and key financial metrics (cash position of $205.1 million, R\u0026D expenses of $20.7 million, net loss of $26.3 million), along with material clinical program updates including completion of enrollment in TibuSHIELD and TibuSURE trials and initiation of the NEXUS-PMR study.","company_name":"Zura Bio Ltd","ticker":"ZURA","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28166,"accession_number":"0001855644-26-000007","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Zura Bio issued a press release on August 11, 2026 announcing its second quarter 2026 financial results, including consolidated balance sheets and statements of operations for the periods ended June 30, 2026. The disclosure includes key financial metrics (cash position of $205.1 million, R\u0026D expenses of $20.7 million, net loss of $26.3 million) and operational updates on clinical programs, which is the standard format for an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:37:00.157596+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28167,"accession_number":"0001855644-26-000007","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation, but the substantive content furnished is Exhibit 99.1, which is a formal earnings release announcing \"Second Quarter 2026 Financial Results and Recent Corporate Updates.\" The release includes consolidated balance sheets, statements of operations, and detailed financial metrics (cash position of $205.1 million, R\u0026D expenses of $20.7 million, net loss of $26.3 million for Q2 2026), along with material clinical program updates (completion of enrollment in TibuSHIELD and TibuSURE trials, initiation of NEXUS-PMR study). This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:37:00.157596+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28166,"accession_number":"0001855644-26-000007","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Zura Bio issued a press release on August 11, 2026 announcing its second quarter 2026 financial results, including consolidated balance sheets and statements of operations for the periods ended June 30, 2026. The disclosure includes key financial metrics (cash position of $205.1 million, R\u0026D expenses of $20.7 million, net loss of $26.3 million) and operational updates on clinical programs, which is the standard format for an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:37:00.157596+00:00","company_name":"Zura Bio Ltd","ticker":"ZURA","filing_date":"2026-08-11"},{"id":28167,"accession_number":"0001855644-26-000007","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation, but the substantive content furnished is Exhibit 99.1, which is a formal earnings release announcing \"Second Quarter 2026 Financial Results and Recent Corporate Updates.\" The release includes consolidated balance sheets, statements of operations, and detailed financial metrics (cash position of $205.1 million, R\u0026D expenses of $20.7 million, net loss of $26.3 million for Q2 2026), along with material clinical program updates (completion of enrollment in TibuSHIELD and TibuSURE trials, initiation of NEXUS-PMR study). This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:37:00.157596+00:00","company_name":"Zura Bio Ltd","ticker":"ZURA","filing_date":"2026-08-11"}]}